Sofosbuvir-Velpatasvir-Voxilaprevir for Chronic Hepatitis C - A Review

Ravari, Alireza Fakhri; Park, Lauren Soojung

doi:10.15406/ghoa.2017.07.00254

Cited by 1 publication

(1 citation statement)

References 49 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…For treatment-experienced patients, especially NS5Aexperienced patients, sofosbovir-velpatasvir-voxilaprevir is generally preferred over GLE/PIB due to shorter 12 weeks of treatment and proven efficacy data. 114 Regardless, GLE/PIB has an essential place in the treatment of HCV, which is vital for achieving World Health Organization's 2030 elimination targets.…”

Section: Discussionmentioning

confidence: 99%

Glecaprevir-pibrentasvir for chronic hepatitis C – a clinical review

Ravari¹,

Nguyen²,

Garcia³

2022

GHOA

View full text Add to dashboard Cite

Hepatitis C virus (HCV) infection has a significant global burden with complications that include hepatocellular carcinoma, decompensated cirrhosis, and the need for liver transplantation to avoid death. Although many treatment options are available for treatment of HCV infections, treatment often requires at least 12 weeks of therapy, which may be complicated by HCV genotype, the need for addition of ribavirin, presence of advanced liver disease, end-stage kidney disease, prior treatment failure, and presence of resistance-associated substitutions. Glecaprevir-pibrentasvir is a pangenotypic, ribavirin-free treatment option approved for ages 3 years or older. This regimen can be used in patients with end-stage kidney disease, has a high-barrier to resistance, and has a shorter treatment duration of 8 weeks for most patients. The purpose of this review is to evaluate the safety and efficacy of this regimen in adults and children who are infected with HCV, which may be the only treatment option for certain patients.

show abstract

Section: Discussionmentioning

confidence: 99%